HFA 23: Dapagliflozin and Peripheral Arterial Disease in Heart Failure

Подробнее о видео

Dr Jawad Haider Butt (Copenhagen University Hospital, DK) outlines the findings of a patient-level meta-analysis of the DAPA-HF and DELIVER trials, which studied the safety and effectiveness of dapagliflozin on patients with both peripheral arterial disease and heart failure. These trials covered the spectrum of patients with heart failure.

The findings of this meta-analysis suggest that dapagliflozin is effective in reducing the composite of worsening heart failure and cardiovascular death. This beneficial effect is not modified by PAD status. The risk of amputation within this patient cohort was not increased with dapagliflozin treatment as compared to placebo.

Interview Questions:
-What is the importance of this trial?
-What was the patient cohort and study design?
-What is the data presented at HFA 23?
-How should these findings be put into clinical practice?
-What are the next steps?

Recorded on-site at HFA 23 in Prague.

Visit Radcliffe Cardiology:

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:
Follow us on Twitter: